Optimizing Decision-Making in CLL in an Era of Novel Agents

A comprehensive educational program featuring expert insight commentaries an Interactive Treatment Decision Support tool and a series of microeducation modules to fortify your practice in managing patients with CLL.

Share

Program Content

Activities

1L: High-Risk Patient
Cases in CLL: High-Risk Patient Requiring First-line Therapy
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

1L: Fit Patient
Cases in CLL: Fit, Younger Patient Requiring First-line Therapy
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

2L: Post-CIT Therapy
Cases in CLL: Second-Line Therapy Following Chemoimmunotherapy
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

2L+: Ibrutinib Intolerance
Cases in CLL: Patient Progressing on BR With Subsequent Ibrutinib Intolerance
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2020

Expires: September 30, 2021

1L: Older Patient
Cases in CLL: Options for an Older Patient Requiring First-line Therapy
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: October 12, 2020

Expires: October 11, 2021

3L: Post BTKi/VenR
Cases in CLL: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

Activities

1L: High-Risk Patient
Cases in CLL Slides: High-Risk Patient Requiring First-line Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

1L: Fit Patient
Cases in CLL Slides: Fit, Younger Patient Requiring First-line Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

2L: Post CIT
Cases in CLL Slides: Second-Line Therapy Following Chemoimmunotherapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: September 28, 2020

Expires: September 27, 2021

2L+: Ibrutinib Intolerance
Cases in CLL Slides: Patient Progressing on BR With Subsequent Ibrutinib Intolerance
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 01, 2020

Expires: September 30, 2021

1L: Older Patient
Cases in CLL Slides: Options for an Older Patient Requiring First-line Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 12, 2020

Expires: October 11, 2021

3L: Post BTKi/VenR
Cases in CLL Slides: Third-line Treatment Following BTK Inhibitor– and Venetoclax-Based Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

Activities

Ibrutinib + Rituximab
Ibrutinib Plus Rituximab and the Expanding Therapeutic Toolbox for Previously Untreated CLL
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: June 26, 2020

Expires: June 25, 2021

CLL: Expert Perspectives
Expert Perspectives on Key New Evidence in CLL Therapy
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2021

Expires: July 27, 2022

Faculty

cover img faculity

Jeffrey P. DONOTUSESharman, MD

Medical Oncologist
Willamette Valley Cancer Institute and Research Center
Springfield, Oregon

cover img faculity

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine
Harvard Medical School
Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

Matthew S. Davids, MD, MMSc

Director of Clinical Research
Division of Lymphoma
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Anthony Mato, MD, MSCE

Associate Professor
Division of Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

William G. Wierda, MD, PhD

Associate Professor of Medicine
Department of Leukemia
The University of Texas
M.D. Anderson Cancer Center
Houston, Texas

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pharmacyclics an AbbVie Company

Partners

CLL Society

ProCE Banner